AMRX
Amneal Pharmaceuticals, Inc.
18.30$
+1.1%
vs. previous close
Closing price · As of: Sep 17, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 59.6% | 59.6% | 57.5% | 29.6% | 33.0% | 38.7% | 38.6% | 37.2% | 39.7% | 45.3% | 52.0% | |
| – | 6.0% | 2.2% | 5.5% | 4.9% | 4.1% | 8.5% | 6.3% | 0.7% | 2.6% | 3.2% | 8.5% | |
| – | 6.5% | 2.6% | 5.5% | 4.9% | 4.2% | 8.6% | 6.3% | 0.7% | 2.7% | 3.2% | 8.5% | |
| – | 27.0% | 32.4% | 26.2% | 13.0% | 16.5% | 16.0% | 17.6% | 19.5% | 18.6% | 22.2% | 25.6% | |
| – | 23.2% | 21.8% | 21.2% | 10.5% | 10.4% | 12.2% | 12.4% | 14.0% | 16.7% | 17.5% | 16.5% | |
| – | 21.1% | 33.4% | 36.3% | 12.5% | 16.9% | 11.9% | 13.1% | 12.4% | – | – | – | |
| – | 2.9% | 2.3% | 2.0% | 9.8% | 11.4% | 13.1% | 15.1% | 15.8% | 17.2% | 17.1% | 16.2% | |
| – | 4.9% | 3.8% | 3.3% | 38.0% | 37.7% | 32.6% | 29.6% | 28.8% | 25.6% | 20.9% | 15.3% | |
| – | 118.4% | 114.4% | 128.0% | 79.4% | 90.5% | 91.1% | 90.7% | 94.5% | 98.2% | 101.3% | 99.8% | |
| – | 23.6% | 18.5% | 22.1% | 12.7% | 15.0% | 16.9% | 17.2% | 19.8% | 24.4% | 32.3% | 24.0% | |
| – | 5.9% | 3.0% | 6.7% | 0.5% | 1.0% | 1.4% | 1.2% | 2.8% | 6.6% | 9.7% | 0.6% | |
| – | 6.9% | 4.9% | 5.2% | 2.6% | 2.8% | 3.8% | 3.3% | 4.4% | 4.1% | 7.4% | 6.9% | |
| – | 41.9% | 66.7% | 101.0% | 60.4% | 71.2% | 68.3% | 68.0% | 68.2% | 69.9% | 61.7% | 69.7% | |
| – | -19.2% | -15.2% | -28.7% | 20.6% | 6.3% | 7.6% | 9.1% | 7.9% | 0.6% | -3.1% | -1.9% | |
| – | -17.9% | -14.4% | -28.5% | -0.5% | -10.3% | -7.2% | -7.0% | -10.7% | -14.1% | -17.3% | -14.5% | |
| 9.8% | 18.6% | 15.5% | 8.6% | 2.9% | 3.6% | 3.7% | 3.9% | 4.0% | 5.1% | 8.8% | 8.8% |
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.